Blue Water Biotech Inc
Blue Water Biotech Inc (ticker: ONCO) is a micro‑capitalisation biotechnology company. With a market capitalisation of roughly $5.66 million, it is likely to be an early‑stage or development‑focused firm where value depends heavily on clinical or research milestones, partnerships and funding. Investors should expect high volatility, possible equity dilution as the company raises cash, and binary outcomes tied to trial results or regulatory decisions. Because public information on very small biotechs can be limited, it’s important to review company filings, press releases and cash runway before forming an opinion. This summary is for general, educational purposes only and is not personalised investment advice. The stock may suit investors who understand biotech risk and are prepared for potential total loss; it may be unsuitable for conservative or short‑term investors. Always consider seeking independent financial advice and be aware that past performance does not predict future results.
Stock Performance Snapshot
Financial Health
Blue Water Biotech Inc is generating modest revenue and cash flow, with a solid book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ONCO
Alternative Cancer Therapies Focus Shifts 2025
The FDA's new boxed warning for Johnson & Johnson and Legend Biotech's cancer drug highlights potential safety issues in CAR-T therapies. This could shift focus to companies developing alternative and potentially safer oncology treatments.
Published: October 13, 2025
Explore BasketCancer Drug Safety: Could Warnings Create Opportunities?
The FDA's decision to add its strongest safety warning to a key cancer therapy from Johnson & Johnson and Legend Biotech underscores the inherent risks of powerful new treatments. This regulatory action could boost companies developing safer alternative cancer therapies, creating a new investment opportunity in the biotech sector.
Published: October 11, 2025
Explore BasketPharma's Next Big Deal
This carefully curated group of stocks features promising biotech companies with valuable drug pipelines. These smaller firms could become the next targets for lucrative partnerships or acquisitions by pharmaceutical giants, similar to Glenmark's recent $2 billion deal with AbbVie.
Published: July 11, 2025
Explore BasketThrill & Excitement Fund
Ready for an investing adventure? This collection features carefully selected stocks with explosive growth potential. Our professional analysts have identified companies at the cutting edge of space tourism, biotech breakthroughs, and digital gaming — all poised to potentially redefine their industries.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Trial readouts matter
Clinical results and milestones can cause sharp share moves; outcomes are binary and may significantly affect valuation.
Funding and dilution
With a very small market cap, the company may need to raise cash; investors should watch the cash runway and potential equity dilution.
Regulatory pathway impact
Regulatory approvals and partnerships shape long‑term value, but setbacks can reduce investor returns; diversify and consider risk tolerance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
